 | Pieter Kappetein, MD, PhD presented the two-year results of the SYNTAX trial at the European Society of Cardiology Meeting, Barcelona on September 2nd, 2009. SYNTAX was featured in a Clinical Trial webcast. Key findings included: - In the SYNTAX randomized patients, 2-year MACCE rates remained significantly higher for PCI than CABG, mainly driven by higher repeat revascularization in the PCI arm.
- MACCE rates at 2 years not significantly different for patients with a low (0-22) or intermediate (23-32) baseline SYNTAX Score treated with either PCI or CABG; for patients with high SYNTAX Scores (≥33), MACCE continued to be increased at 2 years in patients treated with PCI compared with CABG
- In the predefined subgroups of patients with either 3VD or LM disease:
- In the LM group, safety outcomes and MACCE rates were similar for PCI and CABG, but the 2-year revascularization rate was lower in the CABG group.
- Safety outcomes (death/CVA/MI) in the 3VD group were similar for PCI and CABG, but the 2-year revascularization and MACCE rates favored CABG.
The full presentation can be viewed or downloaded here: Presentation: SYNTAX 2 year results, ESC 2009 |
